ABL Bio Inc. (KOSDAQ:298380)
South Korea
· Delayed Price · Currency is KRW 142,000
+2,600 (1.87%)
Apr 29, 2026, 3:30 PM KST
ABL Bio Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -37,806 | -55,529 | -2,647 | 3,209 | -43,558 |
| Depreciation & Amortization | 3,449 | 2,410 | 2,590 | 2,325 | 2,158 |
| Loss (Gain) From Sale of Assets | 8.52 | 7.03 | 2.64 | -48 | 5.83 |
| Loss (Gain) From Sale of Investments | -384.69 | -391.27 | -1,132 | 592.13 | -6,666 |
| Stock-Based Compensation | 5,437 | 2,889 | 6,001 | 4,382 | 7,521 |
| Provision & Write-off of Bad Debts | - | - | - | - | -682.58 |
| Other Operating Activities | -85.45 | 2,004 | -203.88 | 1,352 | -15.18 |
| Change in Accounts Receivable | -59,112 | - | - | - | - |
| Change in Unearned Revenue | 53,339 | -25,976 | -31,859 | 63,562 | -3,160 |
| Change in Other Net Operating Assets | -6,099 | 5,184 | -1,113 | -3,242 | 3,792 |
| Operating Cash Flow | -41,253 | -69,403 | -28,362 | 72,132 | -40,605 |
| Capital Expenditures | -20,065 | -9,023 | -5,740 | -2,055 | -1,244 |
| Sale of Property, Plant & Equipment | 35.65 | 12.78 | 7.46 | 74.51 | 12 |
| Cash Acquisitions | - | - | - | -21,256 | - |
| Sale (Purchase) of Intangibles | -605.69 | -34.75 | -104.41 | -330.07 | -21.4 |
| Sale (Purchase) of Real Estate | - | - | - | -1,252 | - |
| Investment in Securities | 81,796 | -38,152 | 35,941 | -46,234 | 21,458 |
| Other Investing Activities | 752.77 | 22.43 | -20.49 | -196.46 | 17.62 |
| Investing Cash Flow | 62,113 | -47,174 | 29,884 | -71,250 | 20,221 |
| Long-Term Debt Issued | 12,000 | - | 44,831 | - | - |
| Long-Term Debt Repaid | -675.94 | -1,278 | -43,130 | -1,091 | -959.45 |
| Net Debt Issued (Repaid) | 11,324 | -1,278 | 1,701 | -1,091 | -959.45 |
| Issuance of Common Stock | 21,221 | 145,857 | 1,717 | 5,753 | 1,256 |
| Other Financing Activities | -26.18 | -7.39 | -1,981 | -11.67 | -12.36 |
| Financing Cash Flow | 32,519 | 144,572 | 1,437 | 4,649 | 284.13 |
| Foreign Exchange Rate Adjustments | 2,314 | 229.74 | -29.86 | -1,984 | 1,030 |
| Net Cash Flow | 55,693 | 28,225 | 2,929 | 3,547 | -19,070 |
| Free Cash Flow | -61,318 | -78,426 | -34,102 | 70,076 | -41,850 |
| Free Cash Flow Margin | -77.28% | -234.79% | -52.03% | 104.12% | -784.87% |
| Free Cash Flow Per Share | -1190.60 | -1633.14 | -712.77 | 1473.23 | -890.99 |
| Cash Interest Paid | 1,132 | 165.07 | 2,521 | 1,205 | - |
| Cash Income Tax Paid | 112.89 | -1,346 | 1,621 | -2.6 | -75.7 |
| Levered Free Cash Flow | -52,541 | -62,856 | -37,710 | 63,171 | - |
| Unlevered Free Cash Flow | -51,920 | -62,833 | -36,365 | 64,000 | - |
| Change in Working Capital | -11,871 | -20,792 | -32,972 | 60,320 | 631.38 |
Source: S&P Capital IQ. Standard template. Financial Sources.